AR073459A1 - COMPOSITIONS OF VARIABLE DOMAINS OF MONOVALENT ANTIBODIES FOR THE UNION OF CD28 AND METHODS OF USE - Google Patents

COMPOSITIONS OF VARIABLE DOMAINS OF MONOVALENT ANTIBODIES FOR THE UNION OF CD28 AND METHODS OF USE

Info

Publication number
AR073459A1
AR073459A1 ARP090102733A ARP090102733A AR073459A1 AR 073459 A1 AR073459 A1 AR 073459A1 AR P090102733 A ARP090102733 A AR P090102733A AR P090102733 A ARP090102733 A AR P090102733A AR 073459 A1 AR073459 A1 AR 073459A1
Authority
AR
Argentina
Prior art keywords
antibody
variable domain
monovalent
methods
single variable
Prior art date
Application number
ARP090102733A
Other languages
Spanish (es)
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Ltd filed Critical Domantis Ltd
Publication of AR073459A1 publication Critical patent/AR073459A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Se relaciona con un dominio de polipéptido monovalente que se une de manera específica a CD28, al igual que con un antagonista de CD28, donde el antagonista comprende un dominio de polipéptido monovalente que se une de manera especifica a CD28. Dominios de polipéptidos monovalentes que comprenden un dominio variable simple de anticuerpo que se une de manera monovalente a CD28. Un dominio variable simple de anticuerpo que es monovalente para la union de CD28 puede inhibir la actividad de CD28. En un aspecto, un dominio variable simple de anticuerpo anti-CD28 monovalente comprende o consiste en un dominio variable simple de anticuerpo que se une de manera específica a CD28 y antagonista su actividad, en un aspecto, sin agonizar de manera sustancial la actividad de CD28. En otro aspecto, el dominio variable simple de anticuerpo anti-CD28 monovalente es un dominio variable simple de anticuerpo humano. Además contempla métodos para la antagonizacion de las interacciones de CD80 y/o CD86 con CD28 en un individuo, y métodos para el tratamiento de enfermedades o trastornos que involucran interacciones de CD80 y/o CD86 con CD28; donde los métodos comprenden la administracion de un dominio variable simple de anticuerpo anti-CD28 monovalente al individuo.It relates to a monovalent polypeptide domain that specifically binds to CD28, as well as a CD28 antagonist, where the antagonist comprises a monovalent polypeptide domain that specifically binds to CD28. Monovalent polypeptide domains comprising a single variable domain of antibody that binds monovalently to CD28. A simple variable domain of antibody that is monovalent for CD28 binding can inhibit CD28 activity. In one aspect, a single variable domain of monovalent anti-CD28 antibody comprises or consists of a single variable domain of antibody that specifically binds to CD28 and antagonizes its activity, in one aspect, without substantially agonizing CD28 activity. . In another aspect, the single variable domain of monovalent anti-CD28 antibody is a simple variable domain of human antibody. It also contemplates methods for the antagonization of the interactions of CD80 and / or CD86 with CD28 in an individual, and methods for the treatment of diseases or disorders that involve interactions of CD80 and / or CD86 with CD28; where the methods comprise the administration of a single variable domain of monovalent anti-CD28 antibody to the individual.

ARP090102733A 2008-07-18 2009-07-17 COMPOSITIONS OF VARIABLE DOMAINS OF MONOVALENT ANTIBODIES FOR THE UNION OF CD28 AND METHODS OF USE AR073459A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17603608A 2008-07-18 2008-07-18
US755308P 2008-07-18 2008-07-18

Publications (1)

Publication Number Publication Date
AR073459A1 true AR073459A1 (en) 2010-11-10

Family

ID=41316544

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102733A AR073459A1 (en) 2008-07-18 2009-07-17 COMPOSITIONS OF VARIABLE DOMAINS OF MONOVALENT ANTIBODIES FOR THE UNION OF CD28 AND METHODS OF USE

Country Status (4)

Country Link
EP (1) EP2315778A2 (en)
JP (1) JP2012507260A (en)
AR (1) AR073459A1 (en)
WO (1) WO2010007376A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
US20170081411A1 (en) 2014-03-15 2017-03-23 Novartis Ag Regulatable chimeric antigen receptor
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
ES2781175T3 (en) 2014-07-31 2020-08-31 Novartis Ag Optimized subset of T cells containing a chimeric antigen receptor
CN106397592A (en) * 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 Single-domain antibody directed at programmed death ligand (PD-L1) and derived protein thereof
CA3132021C (en) * 2015-11-18 2024-03-12 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
EP3377527A1 (en) * 2015-11-18 2018-09-26 Merck Sharp & Dohme Corp. Ctla4 binders
CN107400166A (en) * 2016-05-19 2017-11-28 苏州康宁杰瑞生物科技有限公司 for CTLA4 single domain antibody and its derived protein
AU2019287765A1 (en) 2018-06-15 2021-01-07 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
MA55805A (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc METHODS OF MODULATING IMMUNE ACTIVITY
JP2023509359A (en) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド Combination anticancer therapy with inducers of iron-dependent cell degradation
CA3184366A1 (en) 2020-06-29 2022-01-06 Darby Rye Schmidt Viruses engineered to promote thanotransmission and their use in treating cancer
CN117534761A (en) * 2023-11-20 2024-02-09 上海百英生物科技股份有限公司 anti-CD28 nano antibody and preparation method and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051227A (en) * 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
CA2672595A1 (en) * 2006-12-15 2008-06-19 Guy Hermans Amino acid sequences that modulate the interaction between cells of the immune system

Also Published As

Publication number Publication date
WO2010007376A3 (en) 2010-05-27
JP2012507260A (en) 2012-03-29
WO2010007376A2 (en) 2010-01-21
EP2315778A2 (en) 2011-05-04

Similar Documents

Publication Publication Date Title
AR073459A1 (en) COMPOSITIONS OF VARIABLE DOMAINS OF MONOVALENT ANTIBODIES FOR THE UNION OF CD28 AND METHODS OF USE
CO6341641A2 (en) MONOVALENT COMPOSITIONS FOR UNION TO CD28 AND METHODS OF USE
BR112012023010A8 (en) ANTIBODY OR ANTIGEN-BINDING FRAGMENT OF THE SAME THAT SPECIFICALLY BINDS TO CD37, IMMUNOCONJUGATE COMPRISING THE SAME, USE OF THE SAID ANTIBODY, FRAGMENT AND IMMUNOCONJUGATE, COMPOSITION COMPRISING THE SAME, KIT, ISOLATED CELL, AS WELL AS IN VITRO METHOD TO INHIBIT GROWTH MENT OF A CELL THAT EXPRESSES CD37
BR112013007314A2 (en) anti-cd48 antibodies and their uses
EP2331136A4 (en) Frizzled-binding agents and uses thereof
EA201370066A1 (en) MODULATORS OF ESTROGEN RECEPTORS AND THEIR APPLICATION
AR077333A1 (en) HIGH AFFINITY HUMAN ANTIBODIES FOR HUMAN ANGIOPOYETIN -2
EA201390472A1 (en) NEW MOLECULES CONNECTING WITH EGFR AND THEIR IMMUNOCONJUGATES
EA201590590A1 (en) ANDROGEN RECEPTOR MODULATORS AND THEIR APPLICATION
MY159679A (en) Antibodies binding preferentially human csf1r extracellular domain 4 and their use
EA201071291A2 (en) NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROPSYATRIC DISORDERS
PE20140673A1 (en) NEW MODULATORS AND METHODS FOR THEIR USE
EA200901166A1 (en) CONNECTIONS AND COMPOSITIONS AS GPR 119 ACTIVITY MODULATORS
DOP2012000246A (en) COMPOSITIONS OF ANTI-FACTOR ANTI-FACTOR OF NERVOUS GROWTH (NGF)
EA201001329A1 (en) COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS
EA200602243A1 (en) 3-AMINOCYCLOPENTANCARBOXAMIDES AS CHEMOKINE RECEPTOR MODULATORS
BR112012020273A2 (en) PYRAZOLOPYRIDINE COMPOUNDS, PIRAZOLOPYRAZINE, PYRAZOLOPYRIMIDINE, PYRAZOLOTHIOPHENE AND PYRAZOLOTHIAZOLE AS MGLUR4 ALLOSTERIC POINTENTIALIZERS, COMPOSITIONS AND METHODS OF TREATMENT OF NEUROLOGICAL DYSFUNCTION
BR112014007426A2 (en) antibodies against tl 1a and their uses
UY31622A1 (en) ANTHOGONISTS OF AMINOALQUILBIFENILO N, N-DISUBSTITUIDOS OF PROSTAGLANDINA D2 RECEPTORS
EA201001332A1 (en) COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS
BR112012018766A2 (en) methods of treating autoimmune diseases with dll4 antagonists.
ECSP099296A (en) IMMUNO-REGULATORS, PREPARATIONS AND COMPOSITIONS INCLUDING IMMUNO-REGULATORS, TESTS TO EVALUATE THE ACTIVITY OF IMMUNO-REGULATORS AND PREPARATIONS AND COMPOSITIONS INCLUDING THE SAME AND METHODS
EA201291180A1 (en) COMPOSITIONS AND METHODS OF APPLICATION OF THERAPEUTIC ANTIBODIES AGAINST PROTEIN RELATED TO LOW DENSITY 6 LIPOPROTEIN RECEPTOR (LRP6)
PE20141158A1 (en) THE PROLACTIN MAT3 RECEPTOR NEUTRALIZING ANTIBODY AND ITS THERAPEUTIC USE
EA201001330A1 (en) COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS

Legal Events

Date Code Title Description
FB Suspension of granting procedure